We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio NEW ORLEANS — Young people with type 2 ...
diabetes test strip Findings from a phase 3 study showed that dulaglutide (Trulicity; Lilly) at higher investigational doses demonstrated superiority in significantly reducing hemoglobin A1c in ...
About 3 times as many of the children and teenagers taking dulaglutide had a glycated hemoglobin level of less than 7.0% at 26 weeks compared with those on placebo. Treatment with a once-weekly dose ...
Another glucagon-like peptide-1 (GLP1) agonist, dulaglutide (Trulicity, Lilly), is poised to be a new option for glycemic control in youth ages 10 to 18 with type 2 diabetes, given as a weekly ...
INDIANAPOLIS, June 13, 2020 /PRNewswire/ -- New real-world data showed Trulicity® (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections of semaglutide ...
Adults with type 2 diabetes and mild to moderate chronic kidney disease assigned the once-weekly GLP-1 receptor agonist dulaglutide experienced a similar reduction in HbA1c vs. those assigned insulin ...
SAN FRANCISCO — The once-weekly injectable glucagon-like peptide-1 (GLP-1) agonist dulaglutide (Trulicity, Lilly) for the treatment of type 2 diabetes has significantly reduced the risk of major ...
TORONTO, June 19, 2020 (GLOBE NEWSWIRE) -- New real-world data showed Trulicity® (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections of semaglutide or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback